Wegovy and Ozempic drove Novo Nordisk to record bumper sales since ... Biocon (which already has large-scale peptide ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

GLP-1 medications like Ozempic and Mounjaro can influence the volume of all-cause hospital admissions and bariatric surgeries, two studies suggest. Researchers at Boston-based Harvard Medical School ...

President-elect Donald Trump has promised Kennedy a large role in the new administration and signaled he could be in charge ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Ozempic offered a way out ... Since 2003, Congress has prohibited GLP-1 coverage for weight loss alone under Medicare, the federal program for retirees and people with disabilities.

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Recent studies reinforce that weight loss is not simply an esthetic consideration. It has very real benefits in terms of ...

Spending on GLP-1s in Medicaid has followed broader industry trends, growing significantly over the past several years, according to a ...

The Danish drugmaker plans to introduce a combination drug, CagriSema, that could result in 25% weight loss — higher than ...